Name: Tumor necrosis factor (TNF) alpha - BioCentury Target Profiles - BCIQ
Creator: Biocentury

Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

Company Profiles
Target Profiles
Product Profiles

Explore BCIQ profiles by entering a target name.

REQUEST A FREE TRIAL

BioCentury | Mar 29, 2025

Product Development

Bispecifics for I&I: Bypassing combination complexity

At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases

BioCentury | Nov 7, 2024

Discovery & Translation

Science Spotlight: Multi-epitope antivirals, metastatic transition, and more

BioCentury’s roundup of translational innovations also includes a study from Amgen and a newco spotlight

BioCentury | Aug 30, 2024

Finance

Finance Report: RA, Forbion back immunology play Navigator to develop bispecific

Plus: Series A for oncology play Noetik; China-based DualityBio files for Hong Kong IPO

BioCentury | Aug 27, 2024

Emerging Company Profile

Montai: Mapping chem-bio connections to find human-vetted therapies

Flagship company uses in silico screening to mine ‘Anthromolecules’ as starting points for pills targeting well-validated pathways, with an initial focus on I&I

BioCentury | Aug 1, 2024

Distillery Therapeutics